ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma
{{output}}
Introduction: Lenvatinib is a first-line therapy for hepatocellular carcinoma (HCC), but its clinical efficacy is limited by drug resistance. ABHD17C, a depalmitoylation enzyme involved in HCC progression, has not been investigat... ...
